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Summary The longer survival of neoplastic patients achieved through improvements of therapeutic regimens has increased the relative risk
of developing a second primary tumour (SPT). In this context, conventional cytopathology can define tumour histotype only in a small fraction
of cases. In this study, we have evaluated whether selected combinations of monoclonal antibodies (MAbs) to tumour-associated antigens
(TAAs) can increase the accuracy of conventional morphology in detecting second primary tumours (SPTs) in two particularly difficult areas of
cytodiagnosis, namely that of effusions and pulmonary fine-needle aspirates (FNAs). The immunocytochemical (ICC) analysis of 334
cytological specimens demonstrated that the use of our selected panel of MAbs could allow a more efficient identification of SPTs in
comparison with conventional morphology. This diagnostic improvement was statistically significant (P<0.0001). The present findings show
that the immunophenotyping of effusions and FNAs, providing a more accurate and objective identification of SPTs, may have significant
therapeutic and epidemiological relevance.
Keywords: second neoplasias; cytological diagnosis; immunocytochemistry; metastases
Second primary tumours (SPTs) have been diagnosed more
frequently in recent years during the clinical course of patients
bearing haematopoietic (Abernathy et al, 1986; Tucker et al, 1988)
and solid tumours (Lee, 1986; Kaldor et al, 1987). As early diag-
nosis ofSPTs has majortherapeutic and epidemiological relevance
(Kaldor et al, 1987; Giardini et al, 1993), the development of new
methods for the accurate detection of second malignancies should
be attempted. In this context, exfoliative and FNA cytology may
be considered a valuable and accurate diagnostic technique, easy
to perform on a large scale during the follow-up ofpatients previ-
ously treated for malignant tumours. These methods also have the
advantage ofminimal morbidity and low cost (Koss, 1988). While
this approach has been reported to be highly accurate in identi-
fying metastatic cells, the possibility ofdefining the tumour histo-
type has been far less successful (Friedman et al, 1983; Hajdu et al,
1984). We have previously reported that the use ofselected combi-
nations of MAbs to TAAs can be applied to a number of areas of
cytodiagnosis of solid tumours, thus increasing the accuracy of
conventional morphology in identifying metastases from unknown
primary tumour and in differentiating primary from metastatic
lesions (Mottolese et al, 1993). In the present study, we have
analysed, in a large group ofpatients with a past history of malig-
nancy, whether the use of a similar panel of reagents may also be
useful in detecting SPTs in two areas of cytopathology, which are
particularly difficult on the basis ofmorphological criteria, namely
that ofeffusions and ofpulmonary FNA.
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MATERIALS AND METHODS
Patients
From January 1990 to June 1995, 334 cytological specimens, of
which 91 were pulmonary FNA and 243 pleural and peritoneal
effusions sampled from patients previously treated with chemo
and/or radiotherapy for different malignant tumours, were analysed
both cytologically and immunocytochemically (ICC). The series
consisted of 93 patients with effusions and 52 with solitary or
multiple pulmonary masses, which appeared within 5 years of a
previous tumour, while 189 patients developed effusions (150
cases) or radiologically assessed lung lesions (39 cases) at least 5
years after the first tumour. Only those cases in which morpholog-
ical examination assessed the presence of malignant cells on cyto-
logical specimens have been included in this study. Unsatisfactory
or insufficient specimens were excluded.
Preparation of cell substrates
Pleural and peritoneal effusions were collected in sterile condi-
tions using heparin (Liquemin Roche) as anticoagulant. Samples
were centrifuged at 160 g for 10 min and the recovered cells
were resuspended, after three washings with Hanks' balanced salt
solution (Gibco Laboratories, Paisley, UK), at a density of 1 x 106
cells ml-'. Red blood cells, when present, were removed by
lysis with Tris/ammonium chloride pH 7.4, for 10 min at 37°C.
Cytospins were obtained using a Shandon cytocentrifuge
(Shandon, Runcorn, Cheshire, UK) and either stained according
to the Papanicolau method for conventional morphological
analysis or fixed in cold absolute acetone and immediately
stored at -20°C for ICC evaluation. Pulmonary FNAs were
performed under computerized tomography (CT) guidance with a
22-gauge needle placed on a 20-ml disposable syringe mounted
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Table 1 Antigenic phenotype of different solid tumours identified with a panel of MAbs to TAAsa
MAbs Antigenic
Phenotype
B72.3 B6.2 MBrI MOv 18-19 OC-125 KSI/4 D612 RC38 PSA Epl-3
+ + + - - NSb - - - - Breast carcinoma
+ - - + + NSb - - - - Ovarian carcinoma
+ - - - + + - - - - Lung carcinoma
+ - - - - - + - - - Colon carcinoma
+ - - - - - - + - - Kidney carcinoma
+ Nsb - - - NSb - - + - Prostate carcinoma
- - - - - - - - - + Melanoma
aSee Mottolese et al (1988, 1989, 1990, 1993, 1994). b NS, not significant to detect tumour origin.
Table 2 Immunocytochemical identification of SPTs in metastatic effusions from patients with a previous history of malignancy
First tumour No. of patients Immunocytochemical diagnosisa
Metastasis Metastasis Undefined
from first tumour from SPTs malignant tumour
Breast carcinoma 95 74 8 Ovarian 7
3 Lung
2 Colon
1 Kidney
14
Ovarian carcinoma 61 52 2 Breast 6
1 Colon
3
Lung carcinoma 48 39 2 Melanoma 7
Colon carcinoma 17 15 1 Ovarian
1 Lung
2
Melanoma 15 13 2 Lung
Prostate carcinoma 7 6 1 Lung
Total 243 199 24 20 (8.2%)
aPerformed according to the pattern of reactivity summarized in Table 1.
on a special holder (Cameco 20 ml, Precision Dynamics,
Burbank, CA, USA). Cellular specimens, smeared onto acid-
clean glass slides, were fixed in 95% ethanol for conventional
cytological diagnosis and in cold absolute acetone for ICC
analysis.
Monoclonal antibodies and immunocytochemical
assays
In order to identify the primary tumour site, we selected a large
panel of MAbs directed to different TAAs. For the purpose ofthis
study, we classified the reagents on the basis oftheir main tumour
specificity, as follows.
MAbs against breast cancer-associated antigens
MAbs B72.3 and B6.2 were commercially obtained from Sorin
Biomedica (Saluggia, Italy), while MAb MBrl was kindly provided
by Professor MI Colnaghi (National Cancer Institute, Milan, Italy).
MAb B72.3 identifies a high molecular weight glycoprotein
expressed by the majority ofadenocarcinomas and by 70% ofbreast
carcinomas independent ofhistotype (Thor et al, 1986). MAb B6.2,
which reacts with 80% of mammary adenocarcinomas, is also
expressed by polymorpholeucocytes and by a high fraction of
pulmonary andprostatecarcinomas (Colcheretal, 1981). MAb MBrl
recognizes a cell membrane neutral glycolipidic antigen, expressed
by normal mammary epithelial cells, in about 70% of breast carci-
nomas and40% ofovarian carcinomas (Canevari etal, 1983).
MAbs againstovarian cancer-associated antigens
MAbs MOvl8 and MOvl9 were obtained from Professor MI
Colnaghi (National Cancer Institute, Milan, Italy) and MAb OC-
125 from Cis Diagnostici (Tronzano Vercellese, Italy). The first
two reagents display a highly restricted tumour specificity with
85% of serous and endometrioid ovarian carcinomas (Miotti et al,
1987), while the glycoprotein Ca-125, expressed by 80% of
non-mucinous ovarian epithelial malignant tumours (Bast et al,
1991), is also present in 70% of non-small-cell lung carcinomas
and in normal bronchial epithelium (Nouwen et al, 1986). In our
study this antigen was detectable on activated mesothelial cells in
only a small percentage ofpleural and peritoneal effusions.
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Table 3 Immunocytochemical identification of SPTs in pulmonary FNA of patients with a past history of malignancy
First tumour No. of patients Immunocytochemical diagnosisa
Metastasis Metastasis SPTb Undefined
from the first-tumour from a SPT
Breast carcinoma 30 25 3 2
Ovarian carcinoma 12 11 ic
Colon carcinoma 6 4 2
Melanoma 9 6 3
Head and neck carcinoma 10 - 2d 2 6
Bladder carcinoma 3 1 2
Kidney carcinoma 5 4 1
NH lymphoma 16 12 4
Total 91 63 3 17 8 (8.8%)
aPerformed according to the pattern of reactivity summarized in Table 1. bLung carcinoma. cBreast carcinoma. dOne prostate carcinoma and one colon
carcinoma. NH, non-Hodgkin's.
Table 4 Comparison between diagnostic potential of cytology and immunocytochemistry in identifying SPTs in effusions and pulmonary FNAs
First tumour No. of patients Metastasis Second tumour Undefined malignant tumour
Cytology ICC Cytology ICC Cytology ICC
Breast carcinoma 125 97 99 7 17 21 9
Ovarian carcinoma 73 61 63 0 4 12 6
Lung carcinoma 48 37 39 0 2 11 7
Colon carcinoma 23 17 19 2 4 4 0
Melanoma 24 14 19 1 5 9 0
Prostate carcinoma 7 5 6 0 1 2 0
Head and neckcarcinoma 10 1 0 0 4 9 6
NH lymphoma 16 11 12 3 4 2 0
Kidney carcinoma 5 4 4 0 1 1 0
Bladder carcinoma 3 1 1 1 2 1 0
Total 334 248 262a 14 44a 72 (21.5%) 28 (8.3%)
aThe diagnostic improvement obtained through ICC analysis was statistically significant in comparison with standard cytology. P<0.0001 (McNemar's test). NH,
non-Hodgkin's.
MAbs againstlung, gastrointestinal, prostate and renal
carcinomas
MAb KS1/4, directed to a lung cancer-associated antigen, kindly
provided by Dr Reisfeld (Scripps Clinic, La Jolla, CA, USA),
reacts with 95% of lung carcinomas, including small-cell lung
cancer, and stains epithelial alveolar cells faintly and hetero-
geneously (Varky et al, 1984).
MAb D612 identifies 85% of primary and metastatic gastro-
intestinal carcinomas and was obtained from Dr J Schlom (NHI,
Bethesda, USA) (Muraro et al, 1989). MAbs L1838 (PSA)
(Dakopatts, Copenhagen, Denmark) and RC38 (Unipath Spa, Italy)
demonstrate a highly restricted tumour specificity for prostatic
(95%) and renal (97%) carcinomas respectively (Gallec et al, 1986,
Oosterwijk et al, 1986).
MAbs against melanoma-associatedantigens.
MAbs HMB45 (Gown et al, 1986) and Epl-3 (Giacomini et al,
1987) were obtained from Dako and Immunology Laboratory,
Regina Elena Cancer Institute, Rome, Italy respectively. MAb
Epl-3, which recognizes a high molecular weight melanoma-
associated antigen (HMW-MAA), is made up by mixing
equimolar concentrations of three reagents, Epl, Ep2, Ep3. This
pool of reagents demonstrates a restricted reactivity with both
primary and metastatic melanoma, and also in amelanotic cells.
MAbs to intermediate filaments andlymphoidantigens
Additional ICC stainings were performed, in some instances,
employing MAbs anti-paqcytokeratins (MNF116), anti-human
leucocyte common antigen (CD45), anti-T cell (CD3 and CD45RO)
and anti-B cell (CD45RA and CD20), purchased from Dako.
The pattern of reactivity of these reagents is described in
Table 1. The use ofmultiple MAbs, as we previously demonstrated
on a large number of different cytological specimens, is imposed
by the lack of absolute tumour specificity of the selected reagents
and by the need to overcome the heterogeneous expression of
TAAs, which may often result in false-negative findings.
(Mottolese et al, 1988, 1989, 1993, 1994).
The immunoreactivity of the MAbs was controlled repeatedly
during the study using negative and positive control specimens.
Cytological preparations were stained employing a sensitive
biotin-streptavidin-immunoperoxidase method (LSAB Kit, Dako),
and the enzymatic activity was developed with 3-amino-9-ethyl-
carbazole using Mayer's haematoxylin as nuclear counterstaining.
Slides were mounted in aqueous mounting medium (Glycergel,
Dako). The ICC findings were evaluated independently by two
investigators who had no knowledge of the cytopathological diag-
nosis. The cytological and immunocytochemical findings were
compared with those obtained by histopathology and/or with the
clinical data obtained during patient follow-up.
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Table 5 Comparison between ICC diagnoses of SPTs and clinical and
pathological data obtained during the patient follow-up
First tumour No. of No. of SPTs Confirmed diagnoses
patients ICC diagnosed by clinical and
pathological data
Breast carcinoma 125 17 15
Ovarian carcinoma 73 4 2
Lung carcinoma 48 2 1
Colon carcinoma 23 4 3
Melanoma 24 5 5
Prostate carcinoma 7 1 1
Head and neck carcinoma 10 4 4
Bladder carcinoma 3 2 2
NH lymphoma 16 4 4
Kidney carcinoma 5 1 0
Total 334 44 37a
a84% correlation with ICC diagnosis.
RESULTS
Immunocytochemical identification of SPTs in
metastatic effusions from patients with a past history
of malignancy
A total of 243 pleural or peritoneal effusions, which appeared in
patients with a past history of malignancy, were analysed ICC
using the panel ofMAbs described in Table 1. This combination of
reagents, in which both positive and negative immunoreactivities
bear diagnostic information, identifies distinct antigenic pheno-
types that can help to discriminate solid tumours of most common
occurrence. As summarized in Table 2, 199 of the 243 effusions
were defined, on the basis of their immunophenotype, as
metastatic from the first tumour. In 24 patients, on the other hand,
immunocytology suggested the presence of a metastasis from a
SPT. Fourteen of these 24 patients had previously been treated for
breast cancer, and the second malignancy originated in the ovary
(eight cases), in the lung (three cases), in the colon (two cases) and
in the kidney (one case). Three patients had a past history of
ovarian carcinoma, two of whom developed a mammary and a
colon carcinoma respectively. A melanoma appeared in two
patients with a lung carcinoma, and a lung cancer in two
Table 6 Clinical and pathological confirmations of the SPTs immunocytochemically diagnosed
First tumour Clinical presentation No. of ICC Subsequent clinical No. of confirmed Histological diagnoses
of disease cases diagnoses evaluation ICC diagnoses
Breast carcinoma Pleural effusion 3 Lung cancer Bronchoscopy + biopsy 2 1 Adc + 1 undifferentiated
carcinoma
Breast carcinoma Peritoneal effusion 8 Ovarian cancer Laparoscopy + biopsy 7 5 Serous adc +2 undifferentiated
carcinoma
Breast carcinoma Peritoneal effusion 2 Colon cancer Colonoscopy + biopsy 2 2 Undifferentiated adc
Breast carcinoma Peritoneal effusion 1 Renal cancer CT scan + biopsy 1 1 Renal cell carcinoma
Breast carcinoma Pulmonary mass 3 Lung cancer Bronchoscopy + biopsy 3 2 Adc + 1 undifferentiated
carcinoma
17 15
Ovarian carcinoma Pleural effusion 2 Breast cancer Mammography + FNA 1 1 Ductal carcinoma
Ovarian carcinoma Peritoneal effusion 1 Colon cancer Colonoscopy + biopsy 1 1 Undifferentiated adc
Ovarian carcinoma Pulmonary mass 1 Lung cancer Bronchoscopy + biopsy Not confirmed Metastatic ovarian carcinoma
4 2
Lung carcinoma Pleural effusion 2 Melanoma Dermatological exam 1 1 Nodular melanoma
+ surgery (IV Clark lev)
Colon carcinoma Pleural effusion 1 Lung cancer Bronchoscopy + biopsy 1 1 Undifferentiated adc
Colon carcinoma Peritoneal effusion 1 Ovarian cancer Laparoscopy + biopsy 1 1 Serous adc
Colon carcinoma Pulmonary mass 2 Lung cancer Bronchoscopy + biopsy 1 1 Undifferentiated carcinoma
4 3
Melanoma Pleural effusion 2 Lung cancer Bronchoscopy + biopsy 2 2 Undifferentiated carcinoma
Melanoma Pulmonary mass 3 Lung cancer Bronchoscopy + biopsy 3 1 Adc + 2 undifferentiated
5 5 carcinoma
Head and neck carcinoma Pulmonary mass 2 Lung cancer Bronchoscopy + biopsy 2 2 Undifferentiated carcinoma
Head and neck carcinoma Pulmonary mass 1 Colon cancer Colonoscopy + biopsy 1 1 Undifferentiated carcinoma
Head and neck carcinoma Pulmonary mass 1 Prostate cancer Transrectal ecotom. + biopsy 1 1 Adc
4 4
Prostate carcinoma Pleural effusion 1 Lung cancer Bronchoscopy + biopsy 1 1 Undifferentiated carcinoma
Bladder carcinoma Pulmonary mass 2 Lung cancer Bronchoscopy + biopsy 2 1 Adc + 1 undifferentiated
carcinoma
Renal carcinoma Pulmonary mass 1 Lung cancer Bronchoscopy + biopsy Not confirmed Metastatic renal cell carcinoma
NHLymphoma Pulmonary mass 4 Lung cancer Bronchoscopy + biopsy 4 2 Undifferentiated adc
+ 2 undifferentiated carcinoma
Total 44 37
NHL, non-Hodgkin's lymphoma. Adc, adenocarcinoma.
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melanoma-bearing patients. An ovarian and a lung adenocarci-
noma were ICC diagnosed in two patients who had been treated
for a colon carcinoma, while in one patient with a prostate carci-
noma, a lung cancer was diagnosed after 5 years from the previous
tumour. ICC analysis was inconclusive in 20 out of 243 cases
(82%). It is noteworthy that in effusions taken from patients 5
years after the previous neoplasia, the incidence of SPTs was
similar to that observed in patients with a disease-free interval
shorter than 5 years.
Immunocytochemical identification of SPTs in patients
with pulmonary masses appearing within or after 5
years of a previous malignancy
A total of91 patients affected by various non-pulmonary neoplasias
were referred for percutaneous CT-FNA because of the radio-
graphic appearance of a solitary (80) or multiple (l1) pulmonary
nodules ofuncertain metastatic or primitive nature. As summarized
in Table 3, in 63 out of 91 pulmonary FNAs the ICC diagnosis
confirmed the metastatic origin of the pulmonary lesion, while in
the remaining group of patients the immunocytological analysis
identified three pulmonary metastases from a SPT coming from a
new primary breast, prostate and colon carcinoma and 17 SPTs
arising in the lung. In eight out of these 91 cases (8.8%), ICC assay
was not able to indicate the tumour origin.
Comparison between cytological and ICC diagnosis
Table 4 compares the ICC and cytological diagnoses performed on
the entire series of 334 specimens (243 effusions and 91
pulmonary FNAs) included in our study and described in detail in
Tables 2 and 3. This analysis demonstrates that conventional
morphology, although accurately recognizing the malignant nature
of the cells, failed to differentiate between a metastasis from the
previous tumour and a new SPT in 72 out of 334 (21.5%) speci-
mens. All the 72 cases presented morphological features similar to
the primary tumour. On the contrary, in 44 out of these 72 speci-
mens cytologically undefined, ICC could identify 14 metastases
from the first neoplasia and 30 SPTs. This diagnostic improvement
was statistically significant (P<0.0001, McNemar's test). In the
remaining 28 cases of uncertain primary or metastatic nature both
morphologically and ICC, eight metastases from the previous
neoplasia (four breast, two ovary, two head and neck carcinomas)
and two SPTs arising in the lung of patients bearing a previous
breast cancer were detected during the clinical course of the
disease; the last 18 patients were lost to follow-up (FU).
The comparison between the ICC diagnosis of SPTs and the
clinical or pathological data subsequently obtained is reported in
Table 5. The use of the panel ofMAbs on effusions and pulmonary
FNAs allowed us to identify 44 SPTs out of334 cases (13%), 37 of
which have subsequently been confirmed with 84% correlation
between ICC and clinical/pathological findings. In seven cases
(one effusion from a lung, two from a breast, two from an ovarian
carcinoma and two pulmonary FNAs sampled from patients with a
previous colon and a renal carcinoma respectively), the presence
of a SPT, suggested by the immunophenotyping, has never been
clinically documented, therefore the neoplastic lesions were
treated as metastases from the first tumour. Table 6 summarizes
the ways in which the clinical and pathological confirmations of
the 44 SPTs that ICC identified were made. The immunopheno-
typing in this series of patients allowed us to choose the clinical
evaluation most suitable for obtaining additional tissue for the
histopathological assessment. In all, 37 out of 44 SPTs have been
confirmed, firstly, by clinical and imaging data and, subsequently,
by histopathological diagnosis.
DISCUSSION
While SPTs have for a long time been incidental autopsy findings,
an increasing number of these tumours are currently diagnosed
during the follow-up of patients treated for cancer with an inci-
dence ranging from 5% to 30% (Friedman et al, 1983; Cahan,
1977). The causes of the development of SPTs may include
genetic, hormonal, environmental and treatment-related factors
(Cooper et al, 1989). Furthermore, longer survival times, owing to
improved therapeutic results, increase the relative risk of a new
tumour unrelated to the first (Cahan, 1977). Cytopathology is
recognized, at present, as a valuable diagnostic technique in almost
any tumour type; thus, efforts to apply this methodology to the
identification of SPTs are currently ongoing (Golub and Lefemine,
1969; Friedman et al, 1983; Giardini et al, 1993).
A diagnosis of SPT is entertained when, according to the tradi-
tional criteria of Warren and Gates (1932), (1) the cytological find-
ings are compatible with a malignant process; and (2) clear
morphological differences are observed between the examined
specimens and the expected cytology. Nevertheless, in a number of
cases SPTs may present morphological features so similar to the
first tumour that cytological methods are unable to distinguish a
metastasis from a second neoplasia. The most critical differential
diagnosis was between a metastatic and a second primary adeno-
carcinoma, as in the case in which a SPT is subsequent to a lung,
mammary, ovarian or colon adenocarcinoma. In addition, the
differential diagnosis between squamous cell carcinomas and
adenocarcinomas may not be unequivocal in poorly differentiated
tumours (Giardini et al, 1993; Van der Gaast et al, 1996). Also, in
lymphoproliferative diseases, the cytological diagnosis is easily
feasible only when monomorphic cellularity occurred, whereas the
assessment ofa diffuse non-Hodgkin's disease with a polymorphic
cell population is more difficult (Pilotti et al, 1993). A partial
success in overcoming these limitations has been achieved by
combined morphology with immunophenotyping. This has so far
mainly relied on the use of MAbs to intermediate filaments and to
other markers ofrelatively low specificity. Therefore, a significant
number of cases cannot be diagnosed beyond the general term of
'adenocarcinoma' and 'carcinoma' until the histological examina-
tion becomes available (Giardini et al, 1993; Van der Gaast et al,
1996). Because previous studies of ours have shown that the
combined evaluation of a large and well-characterized panel of
MAbs on cytological specimens has the capability of detecting
tumour origin in patients with cryptic tumours (Mottolese et al,
1988, 1989, 1990, 1994), we have routinely used this selected
combination of reagents to establish more critically the diagnostic
accuracy of the method in identifying otherwise undiagnosed
SPTs. The results of this study, which reports our experience over
the last 5 years, clearly demonstrate that this diagnostic approach
offers an unprecedented accuracy in detecting SPTs, mainly in
those lesions clearly malignant on the basis ofcytological features,
in which an undifferentiated morphology cannot permit establish-
ment oftheir primary or metastatic nature.
This is supported by two types of evidence. Firstly, our
immunocytodiagnosis has been consistently confirmed during the
patient follow-up by clinical and/or pathological data in a high
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percentage of cases; secondly, the type of SPTs identified reflects,
in most instances, known epidemiological associations among
neoplasias. As already reported (Lee et al, 1986), we have in fact
found that in breast cancer patients, ovarian carcinoma is the most
frequent SPT irrespective of the disease-free interval. Along the
same lines, in 61 effusions, which appeared in patients with a
previous history of ovarian carcinoma, we could identify one
metastasis from colon and two from breast carcinomas, which are
the most common SPTs in patients bearing this female genital tract
neoplasia (Kaldor et al, 1987). As reported by Abernathy et al
(1986), the occurrence ofa single pulmonary mass in patients with
a previously diagnosed carcinoma or haematopoietic tumour must
always be accurately evaluated with the aim of establishing
whether the lesion is a metastasis from the first neoplasm or a
second primary lung cancer. Our study has indeed shown that in
the group of patients bearing pulmonary nodules, which appeared
after chemo and/or radiotherapy, a second malignancy was
detected in 20 out of 91 cases. Seventeen had a SPT in the lung,
while in three cases the lesion was identified by ICC and subse-
quently clinically and/or pathologically as metastatic from a colon,
a breast and a prostate carcinoma. These findings bear particular
relevance in melanoma patients who have an increased risk of
developing a pulmonary SPT (Perry et al, 1986), and in patients
with head and neck cancer, which most frequently metastatize to
the lung (Cooper et al, 1989; McDonald et al, 1989). In addition,
metastatic melanoma may often be amelanotic, as also evident in
our group of patients, thus raising further diagnostic problems. In
fact, in four of 15 effusions from patients with a past history of
melanoma and in two of 48 effusions from patients with a lung
cancer, cytology failed to recognize melanoma metastatic cells
owing to the lack of pigmentation. In this context, ICC may have
therapeutic implications of particular clinical relevance, since
Hainsworth et al (1991) demonstrated that patients with undiffer-
entiated tumours, diagnosed as metastatic melanoma on the basis
of ICC criteria, may benefit significantly from a cisplatin-based
regimen ofchemotherapy.
In the present study, the comparison with standard diagnosis
showed that ICC was more efficient than cytology in identifying a
tumour coming from a specific second primary tumour rather than
from the original neoplasia. When this methodological approach
was compared statistically with conventional cytology, employing
McNemar's test, a significant (P<0.0001) diagnostic improvement
could be observed. In conclusion, our results indicate that the
immunophenotyping of cytological specimens, allowing more
accurate detection ofa second neoplasia, could provide the pathol-
ogist and the epidemiologist with a molecular survey of these
malignancies and the clinicians with guidelines for correct prog-
nostic evaluations and therapeutic planning.
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